Antibodies
25 September 2012
Seattle Genetics and Millennium Complete Enrollment in Phase III AETHERA Trial of ADCETRIS for Post-Transplant Patients with Hodgkin Lymphoma22 September 2012
U.S. FDA Approves EYLEA (aflibercept) Injection for the Treatment of Central Retinal Vein Occlusion21 September 2012
Roche’s Avastin receives positive opinion from EU authority for the treatment of women with recurrent, platinum-sensitive ovarian cancer21 September 2012
VEGF Trap-Eye (aflibercept ophthalmic injection) Recommended for Approval for the Treatment of Wet Age-Related Macular Degeneration in Europe21 September 2012
MorphoSys’s MOR103 Antibody Demonstrates Excellent Safety and Efficacy in Rheumatoid Arthritis Patients21 September 2012
FDA Approves New Indication For Prolia (Denosumab) For The Treatment Of Bone Loss In Men With Osteoporosis At High Risk For Fracture21 September 2012
ABLYNX AND ITS PARTNER ADVANCE NANOBODY CANDIDATE ALX-0751 IN PRE-CLINICAL DEVELOPMENT18 September 2012
Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections18 September 2012
Merck Withdraws European Filing for Erbitux in NSCLC18 September 2012
Ablynx’s First Inhaled Nanobody Successfully Completes Phase I Study17 September 2012
Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)13 September 2012
Glenmark Pharmaceuticals Announces the Initiation of Phase II Study for GBR 500 for Ulcerative Colitis12 September 2012
KaloBios Initiates Phase 2 Study with KB003 Humaneered Monoclonal Antibody in Severe Asthma11 September 2012
Arsanis Expands Its Anti-Infective Monoclonal Antibody Programs with Additional Grant Support from FFG and EUROSTARS11 September 2012
Theraclone Sciences Presents Phase 1 Results of TCN-032, its Therapeutic Antibody Directed at Influenza A, at ICAAC 201211 September 2012
Visterra Presents Preclinical Results that Shows 100% Prevention and Treatment of Influenza with VIS410, a Novel Engineered Human Antibody10 September 2012
MorphoSys and the University of Melbourne Publish Preclinical Data on the Role of GM-CSF in Inflammatory, Arthritic and Osteoarthritic Pain10 September 2012
Compugen Drug Candidate Demonstrates Attenuation of Autoimmunity and Reestablishment of Immune Balance6 September 2012
Clinical Cancer Research Publishes OncoMed Data Demonstrating Anti-Cancer Activity for Anti-DLL4 (Demcizumab) in Pancreatic Cancer5 September 2012
Baxter Initiates Phase I Clinical Trial With anti-MIF Antibody in Patients with Solid TumorsNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports